Hematin

Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins[1]. Hematin can be used for the research of acute porphyrias and cancer[1][2][3][4][5].

Product Specifications

CAS Number

[15489-90-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/hematin.html

Purity

98.09

Solubility

DMSO : 1.43 mg/mL (ultrasonic; warming; heat to 70°C)

Smiles

CC1=C(CCC(O)=O)C([N-]C1=CC(C(C)=C2C=C)=NC2=CC3=C4C)=CC(C(CCC(O)=O)=C5C)=NC5=CC([N-]3)=C4C=C.[Fe+3].[OH-]

Molecular Formula

C34H33FeN4O5

Molecular Weight

633.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Siegert SW, et al. Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review. Adv Ther. 2008 Sep;25 (9) :842-57.|[2]Green D, et al. The inactivation of hemostatic factors by hematin. J Lab Clin Med. 1983;102: 361-369.|[3]Amin ML, et al. Development of hematin conjugated PLGA nanoparticle for selective cancer targeting. Eur J Pharm Sci. 2016 Aug 25;91:138-43.|[4]Goetsch C, et al. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315: 235-238.|[5]Quadros HC, et al. The Role of the Iron Protoporphyrins Heme and Hematin in the Antimalarial Activity of Endoperoxide Drugs. Pharmaceuticals (Basel) . 2022;15 (1) :60. Published 2022 Jan 4.